Paul Tudor Jones's BMRN Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 105,523 shares of BioMarin Pharmaceutical Inc. (BMRN) worth $6.27 M, representing 0.01% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 32 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in BMRN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 105,523 shares. Largest reduction occurred in Q3 2025, reducing 57,750 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +105,523 | New Buy | 105,523 | $59.43 |
| Q3 2025 | -57,750 | Sold Out | 0 | $0.00 |
| Q2 2025 | -17,316 | Reduce 23.07% | 57,750 | $54.97 |
| Q1 2025 | -24,659 | Reduce 24.73% | 75,066 | $70.69 |
| Q4 2024 | +6,957 | Add 7.50% | 99,725 | $65.73 |
| Q3 2024 | +92,768 | New Buy | 92,768 | $70.29 |
| Q1 2023 | -39,076 | Sold Out | 0 | $0.00 |
| Q4 2022 | +39,076 | New Buy | 39,076 | $0.10 |
| Q2 2022 | -7,976 | Sold Out | 0 | $0.00 |
| Q1 2022 | +7,976 | New Buy | 7,976 | $77.11 |
| Q3 2021 | -2,814 | Sold Out | 0 | $0.00 |
| Q2 2021 | +2,814 | New Buy | 2,814 | $83.51 |
| Q1 2021 | -17,187 | Sold Out | 0 | $0.00 |
| Q4 2020 | +13,368 | Add 350.04% | 17,187 | $87.68 |
| Q3 2020 | +3,819 | New Buy | 3,819 | $76.20 |
| Q1 2020 | -8,036 | Sold Out | 0 | $0.00 |
| Q4 2019 | -28,771 | Reduce 78.17% | 8,036 | $84.49 |
| Q3 2019 | +5,754 | Add 18.53% | 36,807 | $67.41 |
| Q2 2019 | +245 | Add 0.80% | 31,053 | $85.66 |
| Q1 2019 | +5,290 | Add 20.73% | 30,808 | $88.84 |
| Q4 2018 | -8,939 | Reduce 25.94% | 25,518 | $85.16 |
| Q3 2018 | +16,795 | Add 95.09% | 34,457 | $96.96 |
| Q2 2018 | +17,662 | New Buy | 17,662 | $94.21 |
| Q1 2018 | -10,373 | Sold Out | 0 | $0.00 |
| Q4 2017 | -9,392 | Reduce 47.52% | 10,373 | $89.17 |
| Q3 2017 | +3,498 | Add 21.50% | 19,765 | $93.09 |
| Q2 2017 | +16,267 | New Buy | 16,267 | $90.80 |
| Q4 2015 | -6,208 | Sold Out | 0 | $0.00 |
| Q3 2015 | +4,146 | Add 201.07% | 6,208 | $105.35 |
| Q2 2015 | +2,062 | New Buy | 2,062 | $136.76 |
| Q4 2014 | -5,913 | Sold Out | 0 | $0.00 |
| Q3 2014 | +5,913 | New Buy | 5,913 | $72.21 |
Paul Tudor Jones's BioMarin Pharmaceutical Investment FAQs
Paul Tudor Jones first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q3 2014, acquiring 5,913 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held BioMarin Pharmaceutical Inc. (BMRN) for 32 quarters since Q3 2014.
Paul Tudor Jones's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q4 2025, adding 105,523 shares worth $6.27 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 105,523 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $6.27 M.
As of the Q4 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 105,523 shares, as reported at the end of Q4 2025.